GlobalData on MSN3d
Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatmentBiogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet ...
News Medical on MSN5d
Gene therapy breakthrough offers hope for severe Dravet syndrome casesAAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...
In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...
A team of researchers has developed a new gene therapy for children with Dravet syndrome - a rare type of epilepsy in ...
An investigational antisense oligonucleotide, zorevunersen targets the sodium voltage-gated channel alpha subunit 1(SCN1A) gene, which is the primary cause of most Dravet syndrome cases.
Michigan Medicine researchers have developed a SCN1B gene therapy that restores brain function and survival in mice with ...
The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...
Recent research takes aim at the a variant in gene SCN1B, which causes a severe form of developmental epileptic encephalopathy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback